Le ManNAc, une nouvelle thérapie dans la néphropathie à lésions glomérulaires minimes
| Autor: | Camille Macé, Lionel C. Clement |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
First episode Proteinuria business.industry Nephrosis nutritional and metabolic diseases General Medicine Pharmacology medicine.disease eye diseases General Biochemistry Genetics and Molecular Biology Podocyte Pathogenesis 03 medical and health sciences 030104 developmental biology medicine.anatomical_structure ANGPTL4 Albuminuria Medicine Minimal change disease medicine.symptom business |
| Zdroj: | médecine/sciences. 32:606-611 |
| ISSN: | 1958-5381 0767-0974 |
| Popis: | Current therapies used in minimal change disease (MCD) were originally designed to cure other diseases. They are only partially efficient, and present inconvenient side effects. Therefore, understanding the molecular mechanisms implicated in the pathogenesis of proteinuria in MCD could lead to new therapeutic strategies. A new experimental transgenic rat model of human MCD was generated. These NPHS2-Angptl4 transgenic rats over-express two different forms of the glycoprotein Angptl4 from the podocyte. The majority of the protein shows a lack of sialylation that is implicated in the pathogenesis of proteinuria. Supplementation of ManNAc, a precursor of sialic acid, significantly reduces albuminuria in those rats by increasing sialylation of the hyposialylated form of Angptl4. After treatment of the first episode of MCD with glucocorticoids in patients, ManNAc could be used as a maintenance drug, especially to reduce the frequency and intensity of relapse. ManNAc is a promising therapeutic agent for patients with MCD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|